What is the effect of body weight on eculizumab pharmacokinetics?

Nov 18, 2022 ... Early eculizumab withdrawal in patients with atypical hemolytic uremic syndrome in native kidneys is safe and cost-effective: results of the CUREiHUS study Feb 13, 2019 ... Eculizumab (Soliris®, Alexion Pharmaceuticals, Inc., New Haven, CT, USA) is a humanized chimeric monoclonal antibody consisting of a human ... About This Drug. Eculizumab-xxxx (Soliris, Bkemv) is used to treat some blood disorders and nerve disorders. It is given in the vein (IV). View the fact sheet ... A specific anti-complement treatment (eculizumab; its brand name is Soliris) ... If eculizumab is started, how long does it need to be continued? When a ... It is used by specialist doctors to treat two rare conditions called paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic-uraemic syndrome (aHUS). May 28, 2024 ... The US Food and Drug Administration approved Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) to treat certain rare ... Soliris is not expected to affect the aplastic component of anaemia in patients with PNH. Meningococcal Infection. Due to its mechanism of action, the use of ... Sep 19, 2021 ... Eculizumab is an anti-C5 humanized monoclonal antibody that binds to C5, preventing its cleavage into C5a and C5b. Simple Search Results for: SolirisNew SearchNavigate to Advanced Search ; Biosimilar(s) · Epysqli · eculizumab-aagh ; Interchangeable(s) · Bkemv · eculizumab-aeeb. Drug-induced liver injury (DILI), a rare, but potentially life-threatening drug reaction with elevated liver enzymes that may lead to liver failure or a need ...